Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Total revenues	$ 104,754	$ 69,056	$ 68,458
Cost of product revenue	22,209	13,742	15,632
Research and development	55,919	44,185	33,873
Selling, general and administrative	49,323	35,049	31,502
Total costs and operating expenses	127,451	92,976	81,007
Income (loss) from operations	(22,697)	(23,920)	(12,549)
Depreciation expense	3,113	1,950	1,570
Loss before income taxes	(21,090)	(23,671)	(11,918)
Stock-based compensation	11,593	7,728	6,943
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	90,515	48,106	58,156
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	14,239	20,950	10,302
Operating Segments
Segment Reporting Information [Line Items]
Total revenues	104,754	69,056	68,458
Cost of product revenue	22,209	13,742	15,632
Research and development	53,359	42,628	32,658
Selling, general and administrative	14,860	11,952	10,684
Total costs and operating expenses	90,428	68,322	58,974
Income (loss) from operations	14,326	734	9,484
Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	90,515	48,106	58,156
Cost of product revenue	22,209	13,742	15,632
Research and development	23,140	20,923	19,380
Selling, general and administrative	12,105	9,597	8,462
Total costs and operating expenses	57,454	44,262	43,474
Income (loss) from operations	33,061	3,844	14,682
Stock-based compensation	4,514	2,970	2,303
Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	14,239	20,950	10,302
Cost of product revenue	0	0	0
Research and development	30,219	21,705	13,278
Selling, general and administrative	2,755	2,355	2,222
Total costs and operating expenses	32,974	24,060	15,500
Income (loss) from operations	(18,735)	(3,110)	(5,198)
Stock-based compensation	1,100	768	695
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(32,201)	(22,306)	(19,624)
Depreciation expense	3,215	2,099	1,778
Loss before income taxes	(21,090)	(23,671)	(11,918)
Stock-based compensation	5,979	3,990	3,945
Product revenue
Segment Reporting Information [Line Items]
Total revenues	70,657	30,220	29,465
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	70,657	30,220	29,465
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0
Product revenue | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	70,657	30,220	29,465
Product revenue | Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	70,657	30,220	29,465
Product revenue | Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	34,097	38,836	38,993
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	19,858	17,886	28,691
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	14,239	20,950	10,302
Research and development revenue | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	34,097	38,836	38,993
Research and development revenue | Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	19,858	17,886	28,691
Research and development revenue | Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	$ 14,239	$ 20,950	$ 10,302